Sfoglia per Autore
Drug Interactions with Contraceptives
2021 Gatti M.; De Ponti F.
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19
2021 Gatti M.; Fusaroli M.; Caraceni P.; Poluzzi E.; De Ponti F.; Raschi E.
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
2021 Fusaroli M.; Raschi E.; Gatti M.; De Ponti F.; Poluzzi E.
European List of Essential Medicines for Medical Education: A protocol for a modified Delphi study
2021 Donker E.; Brinkman D.; Richir M.; Papaioannidou P.; Likic R.; Sanz E.J.; Christiaens T.; Costa J.; De Ponti F.; Gatti M.; Bottiger Y.; Kramers C.; Garner S.; Pandit R.; Van Agtmael M.; Tichelaar J.
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase
2021 Gatti, Milo; Raschi, Emanuel; Moretti, Ugo; Ardizzoni, Andrea; Poluzzi, Elisabetta; Diemberger, Igor
Janus kinase inhibitors and coronavirus disease (Covid)‐19: Rationale, clinical evidence and safety issues
2021 Gatti M.; Turrini E.; Raschi E.; Sestili P.; Fimognari C.
Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing
2021 Gatti, Milo; Giannella, Maddalena; Raschi, Emanuel; Viale, Pierluigi; De Ponti, Fabrizio
Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study
2021 Rinaldi M.; Bartoletti M.; Ferrarese A.; Franceschini E.; Campoli C.; Coladonato S.; Pascale R.; Tedeschi S.; Gatti M.; Cricca M.; Ambretti S.; Siniscalchi A.; Morelli M.C.; Cescon M.; Cillo U.; Di Benedetto F.; Burra P.; Mussini C.; Cristini F.; Lewis R.; Viale P.; Giannella M.
A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol
2021 Gatti, Milo; Bartoletti, Michele; Cojutti, Pier Giorgio; Gaibani, Paolo; Conti, Matteo; Giannella, Maddalena; Viale, Pierluigi; Pea, Federico
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis
2021 Gatti M.; Rinaldi M.; Ferraro G.; Toschi A.; Caroccia N.; Arbizzani F.; Raschi E.; Poluzzi E.; Pea F.; Viale P.; Giannella M.
Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: A careful appraisal beyond approved indications focusing on unmet clinical needs
2021 Gatti M.; Andreoni M.; Pea F.; Viale P.
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system
2021 Milo Gatti, Ippazio Cosimo Antonazzo, Igor Diemberger, Fabrizio De Ponti, Emanuel Raschi
Quality of care indicators in the MAnageMent of BlOOdstream infections caused by Enterobacteriaceae (MAMBOO-E study): state of the art and research agenda
2021 Giannella M.; Malosso P.; Scudeller L.; Bussini L.; Rebuffi C.; Gatti M.; Bartoletti M.; Ianniruberto S.; Pancaldi L.; Pascale R.; Tedeschi S.; Viale P.; Paul M.
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
2021 Gatti M.; Raschi E.; De Ponti F.
Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis
2021 Gatti M.; Raschi E.; De Ponti F.
Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections
2021 Gatti, Milo; Pea, Federico
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors
2021 Gatti M.; Pea F.
Drug repurposing in the covid-19 era: Insights from case studies showing pharmaceutical peculiarities
2021 Gatti M.; De Ponti F.
Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study
2021 Rinaldi M.; Bartoletti M.; Ferrarese A.; Franceschini E.; Campoli C.; Coladonato S.; Pascale R.; Tedeschi S.; Gatti M.; Cricca M.; Ambretti S.; Siniscalchi A.; Morelli M.C.; Cescon M.; Cillo U.; Di Benedetto F.; Burra P.; Mussini C.; Cristini F.; Lewis R.; Viale P.; Giannella M.
Assessment of adverse reactions to α-lipoic acid containing dietary supplements through spontaneous reporting systems
2021 Gatti M.; Ippoliti I.; Poluzzi E.; Antonazzo I.C.; Moro P.A.; Moretti U.; Menniti-Ippolito F.; Mazzanti G.; De Ponti F.; Raschi E.
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile